Gubra A S

Thank you for standing by. My name is Karen, and I will be your conference separator today. At this time, I would like to welcome everyone to the Gubra Quarter 3 2025 earnings release. All lines have been placed on mute to prevent any background noise. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star followed by the number one on your telephone keypad. To withdraw your question, you may press star followed by the number one again. I will now turn the call over to Marcus Warfield, CEO. Please go ahead.

Good morning, everybody. Also, welcome from my side. My name is Marcus Warfield. I'm the CEO of Coupa. I'm joined here by Luisi, our CSO, and our CFO, Christian. So we'll start with our presentation. I will give a general overview followed by Luise and then the financial results by Christian before I wrap up. As you know, at the core of our strategy, we have a dual business model. We have our discovery partnerships, our key value driver and our CEO services, which are a strong enabler. for our internal pipeline as well as our partnering. Our CEO business has had remarkable growth over the long run. We had 30% growth year-on-year and we deliver great data and service to 16 out of top 20 customers in the pharma and biotech area.

Our primary focus has been obesity, and I think our recent deal with Appion Ammon has demonstrated and validated our business model. Now, let's look at the first nine months. And I think this chart speaks for itself. Obviously, it's going to be a record year for HUBRA, both on the revenue side as well as the margin side driven by the upfront of the extraordinary business update, which has brought us significant liquidity. In terms of highlights for 2025, Of course, our UCM2 program has demonstrated fantastic preclinical results, and we look forward to bringing this asset to the clinic in the first half of 2026. This program is developed for equal high-quality weight loss, and you will hear more about it from the UC. I mentioned the FB deal, obviously this is a milestone deal for us and we have also had an extraordinary dividend of 1 billion UK. Emeline has shown great results and it's called ABB295 now and phase one was very, very And we also have demonstrated great half-life for the product and significant rate reduction. So we strongly believe in the annual growth. Our CEO business has seen a slight decline, driven by macroeconomic uncertainties, which has led to some delays in decision-making among our customers. But we believe there is life at the end of the tunnel. And of course, also new from my side, I joined the company in September this year and I'm excited to lead the team and the company to its full potential. I'm handing over to Louise now.